<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054088</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-00974</org_study_id>
    <nct_id>NCT05054088</nct_id>
  </id_info>
  <brief_title>ImmuneSense COVID-19 Variant Study</brief_title>
  <official_title>ImmuneSense™ COVID-19 Variant Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adaptive Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adaptive Biotechnologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the clinical performance of the T-Detect™ COVID test to identify an&#xD;
      immune response to SARS-CoV-2 infection in the setting of multiple circulating variants of&#xD;
      the SARS-CoV-2 virus. Performance may vary depending on the variants circulating at the time&#xD;
      of testing, including newly emerging strains of SARS-CoV-2 and their prevalence, which&#xD;
      changes over time.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2021</start_date>
  <completion_date type="Anticipated">September 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Objective: Positive Percent Agreement</measure>
    <time_frame>Baseline</time_frame>
    <description>To determine the positive percent agreement (PPA) of the T-Detect™ COVID test with SARS-CoV-2 RT-PCR testing in populations having multiple circulating SARS-CoV-2 variant strains. The primary endpoint is the positive percent agreement (PPA) of the T-Detect™ COVID test with SARS-CoV-2 RT-PCR testing.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Subjects who have tested positive for SARS-CoV-2 by EUA RT-PCR testing with symptoms compatible with SARS-CoV-2 infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Subjects who have tested positive for SARS-CoV-2 by EUA RT-PCR testing with or without symptoms compatible with SARS-CoV-2 infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>T-Detect COVID test</intervention_name>
    <description>• The T-DetectTM COVID test is an EUA granted investigational device that is indicated to assess a T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood will be collected in volumes of 5 mL (1 x 10 mL K2 EDTA tube) for each&#xD;
      participant. It will be considered a protocol deviation if less than 2mL of whole blood is&#xD;
      collected per tube All whole blood samples collected during the study visit will be shipped&#xD;
      ambiently to Adaptive. Upon arrival at Adaptive, blood will undergo DNA extraction, and the&#xD;
      T-Detect TM COVID test will be performed as applicable and per laboratory protocols.&#xD;
      Additional assays may be applied.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Prospective ascertainment of a target of 50 whole blood samples (1 sample per individual),&#xD;
        and a maximum number of 150 whole blood samples, from individuals between the ages of 18-89&#xD;
        who reside within the United States who have tested positive for SARS-CoV-2 infection via&#xD;
        RT-PCR test.&#xD;
&#xD;
        Pregnant women, prisoners, mentally disabled persons, and wards-of-the-state will be&#xD;
        excluded to prevent any risk to these vulnerable populations.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants must satisfy the following criteria to be enrolled in the study:&#xD;
&#xD;
          -  Individuals who have tested positive for SARS-CoV-2 via EUA RT-PCR testing.&#xD;
&#xD;
          -  Male and female participants of any race and ethnicity between 18 to 89 years of age&#xD;
             (inclusive) at the time of enrollment in the study.&#xD;
&#xD;
          -  Must be able to communicate with the investigator, understand, and comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
        Cohort 1 Additional Inclusion Criteria:&#xD;
&#xD;
          -  Must be able to provide estimated date of symptom onset.&#xD;
&#xD;
          -  Must be available for specimen collection greater than 14 days (i.e., 15 days&#xD;
             inclusive onward) and less than 107 days (i.e., 106 days inclusive or less) after&#xD;
             first exhibiting symptoms of confirmed SARS-CoV-2 infection.&#xD;
&#xD;
        Cohort 2 Additional Inclusion Criteria:&#xD;
&#xD;
        ° Must be available for specimen collection greater than 14 days (i.e., 15 days inclusive&#xD;
        onward) and less than 107 days (i.e., 106 days inclusive or less) after first exhibiting&#xD;
        symptoms of confirmed SARS-CoV-2 infection, OR, from date of RT-PCR test if asymptomatic.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The presence of any of the following will exclude a participant from enrollment:&#xD;
&#xD;
          -  Individuals who did not test positive for SARS-CoV-2 on EUA RT-PCR.&#xD;
&#xD;
          -  Protected populations including pregnant women, prisoners, mentally disabled persons,&#xD;
             and wards-of-the state.&#xD;
&#xD;
          -  Any significant condition, laboratory abnormality, or psychiatric illness that would&#xD;
             prevent the participant from safely participating in the study.&#xD;
&#xD;
          -  Exposure to a SARS-CoV-2 investigational drug (new chemical entity) within 60 days&#xD;
             prior to enrollment at the discretion of the Sponsor.&#xD;
&#xD;
          -  Receipt of immunosuppressive medications, such as, but not limited to, recent&#xD;
             moderate- or high-dose systemic steroids or immunomodulators within 1 month prior to&#xD;
             enrollment at the discretion of the Sponsor.&#xD;
&#xD;
          -  Treatment with immunosuppressants/ immunomodulators that do not impact T cells or B&#xD;
             cells may be allowed at the discretion of the Sponsor.&#xD;
&#xD;
          -  Steroid formulations including low-dose oral steroids (≤ 10 mg prednisone equivalents&#xD;
             per day), inhaled steroids, or topical steroids are not considered exclusionary. Doses&#xD;
             &gt;10 and &lt;20 mg prednisone equivalents per day, must receive Sponsor approval.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudeb Dalai, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Adaptive Biotechnologies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katelyn McLeod</last_name>
    <phone>206-279-2426</phone>
    <email>kmcleod@adaptivebiotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jia Qadeer</last_name>
    <phone>+1 (206) 600-6761</phone>
    <email>jqadeer@adaptivebiotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Decentralized Trial Model- California</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>22400</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katelyn McLeod</last_name>
      <phone>253-988-6108</phone>
      <email>cori@curebase.com</email>
    </contact>
    <investigator>
      <last_name>Sudeb Dalai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decentralized Trial Model- Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katelyn McLeod</last_name>
      <email>kmcleod@adaptivebiotech.com</email>
    </contact>
    <investigator>
      <last_name>Sudeb Dalai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decentralized Trial Model- Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katelyn McLeod</last_name>
      <email>kmcleod@adaptivebiotech.com</email>
    </contact>
    <investigator>
      <last_name>Sudeb Dalai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Variant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

